Regulation of histone deacetylase 7 (HDAC7) activity

组蛋白脱乙酰酶 7 (HDAC7) 活性的调节

基本信息

  • 批准号:
    7054094
  • 负责人:
  • 金额:
    $ 24.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-08-01 至 2007-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Many studies have indicated that aberrant recruitment of histone deacetylases (HDACs) may lead to cancer. HDACs are thought to function, in part, by regulating transcriptional activity of DNA-binding transcription factors thereby modulating the expression of a network of genes. Thus, understanding how HDACs regulate transcription and how cellular signaling controls HDAC activity will help to understand deregulated cell growth in cancer and may have therapeutic implications for cancer treatment. HDAC7 (Histone deacetylase 7) belongs to the class II HDACs that includes HDAC4, -5, -6, -9, and -10. Members of the class II HDACs distinguish themselves from class I HDACs by their restricted tissue distribution profiles and notably, their ability to shuttle between the nucleus and the cytoplasm. We hypothesize that the subcellular distribution of HDAC7 is determined by the interplay between its interacting partners. Aim I will elucidate the mechanism of nucleocytoplasmic shuttling of HDAC7. Aim II will characterize the proteolytic pathway regulating HDAC7 degradation. We also discovered that 14-3-3 proteins stabilize HDAC7. Aim III will dissect the mechanism of 14-3-3-dependent stabilization of HDAC7. A combination of fluorescence microscopy, inhibitor, and biochemical approaches will be taken to accomplish these objectives. The results from this study will determine the mechanism by which HDAC7 activity is regulated at the molecular and cellular level. Understanding how cellular signaling controls HDAC activities will help to understand deregulated cell growth in cancer and may have therapeutic implications for cancer treatment.
描述(由申请人提供): 许多研究表明,组蛋白脱乙酰酶(HDAC)的异常募集可能导致癌症。HDAC被认为部分地通过调节DNA结合转录因子的转录活性从而调节基因网络的表达来起作用。因此,了解HDAC如何调节转录以及细胞信号传导如何控制HDAC活性将有助于了解癌症中失调的细胞生长,并可能对癌症治疗具有治疗意义。HDAC 7(组蛋白脱乙酰酶7)属于II类HDAC,其包括HDAC 4、-5、-6、-9和-10。II类HDAC的成员通过其受限的组织分布特征和值得注意的是其在细胞核和细胞质之间穿梭的能力将其自身与I类HDAC区分开。我们假设HDAC 7的亚细胞分布是由其相互作用伙伴之间的相互作用决定的。目的阐明HDAC 7的核质穿梭机制。目的II将表征调节HDAC 7降解的蛋白水解途径。我们还发现14-3-3蛋白稳定HDAC 7。目的III将剖析HDAC 7的14-3-3依赖性稳定机制。将采取荧光显微镜、抑制剂和生物化学方法的组合来实现这些目标。这项研究的结果将确定HDAC 7活性在分子和细胞水平上调节的机制。了解细胞信号传导如何控制HDAC活性将有助于了解癌症中细胞生长失调,并可能对癌症治疗具有治疗意义。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
VEGF stimulates HDAC7 phosphorylation and cytoplasmic accumulation modulating matrix metalloproteinase expression and angiogenesis.
The positive transcription elongation factor b is an essential cofactor for the activation of transcription by myocyte enhancer factor 2.
  • DOI:
    10.1016/j.jmb.2008.07.017
  • 发表时间:
    2008-10-03
  • 期刊:
  • 影响因子:
    5.6
  • 作者:
    Nojima, Masanori;Huang, Yehong;Tyagi, Mudit;Kao, Hung-Ying;Fujinaga, Koh
  • 通讯作者:
    Fujinaga, Koh
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HUNG-YING KAO其他文献

HUNG-YING KAO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HUNG-YING KAO', 18)}}的其他基金

Histone deacetylase 7 and its interacting proteins in endothelial cells
内皮细胞中组蛋白脱乙酰酶 7 及其相互作用蛋白
  • 批准号:
    8440360
  • 财政年份:
    2010
  • 资助金额:
    $ 24.09万
  • 项目类别:
Histone deacetylase 7 and its interacting proteins in endothelial cells
内皮细胞中组蛋白脱乙酰酶 7 及其相互作用蛋白
  • 批准号:
    7780590
  • 财政年份:
    2010
  • 资助金额:
    $ 24.09万
  • 项目类别:
Histone deacetylase 7 and its interacting proteins in endothelial cells
内皮细胞中组蛋白脱乙酰酶 7 及其相互作用蛋白
  • 批准号:
    8215932
  • 财政年份:
    2010
  • 资助金额:
    $ 24.09万
  • 项目类别:
Histone deacetylase 7 and its interacting proteins in endothelial cells
内皮细胞中组蛋白脱乙酰酶 7 及其相互作用蛋白
  • 批准号:
    8015360
  • 财政年份:
    2010
  • 资助金额:
    $ 24.09万
  • 项目类别:
Alpha actinin 4: its functions and regulation
α肌动蛋白4:其功能和调节
  • 批准号:
    7753889
  • 财政年份:
    2009
  • 资助金额:
    $ 24.09万
  • 项目类别:
Alpha actinin 4: its functions and regulation
α肌动蛋白4:其功能和调节
  • 批准号:
    8397678
  • 财政年份:
    2009
  • 资助金额:
    $ 24.09万
  • 项目类别:
Alpha actinin 4: its functions and regulation
α肌动蛋白4:其功能和调节
  • 批准号:
    8225269
  • 财政年份:
    2009
  • 资助金额:
    $ 24.09万
  • 项目类别:
Alpha actinin 4: its functions and regulation
α肌动蛋白4:其功能和调节
  • 批准号:
    7581123
  • 财政年份:
    2009
  • 资助金额:
    $ 24.09万
  • 项目类别:
Alpha actinin 4: its functions and regulation
α肌动蛋白4:其功能和调节
  • 批准号:
    8018500
  • 财政年份:
    2009
  • 资助金额:
    $ 24.09万
  • 项目类别:
Regulation of histone deacetylase 7 (HDAC7) activity
组蛋白脱乙酰酶 7 (HDAC7) 活性的调节
  • 批准号:
    6890278
  • 财政年份:
    2003
  • 资助金额:
    $ 24.09万
  • 项目类别:

相似海外基金

TP-R: a novel mediator of obesity-linked insulin resistance in humans
TP-R:人类肥胖相关胰岛素抵抗的新型介质
  • 批准号:
    10709488
  • 财政年份:
    2021
  • 资助金额:
    $ 24.09万
  • 项目类别:
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS
p53 突变三阴性乳腺癌的精准代谢治疗
  • 批准号:
    10454390
  • 财政年份:
    2021
  • 资助金额:
    $ 24.09万
  • 项目类别:
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS
p53 突变三阴性乳腺癌的精准代谢治疗
  • 批准号:
    10294457
  • 财政年份:
    2021
  • 资助金额:
    $ 24.09万
  • 项目类别:
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS
p53 突变三阴性乳腺癌的精准代谢治疗
  • 批准号:
    10621315
  • 财政年份:
    2021
  • 资助金额:
    $ 24.09万
  • 项目类别:
TP-R: a novel mediator of obesity-linked insulin resistance in humans
TP-R:人类肥胖相关胰岛素抵抗的新型介质
  • 批准号:
    10426085
  • 财政年份:
    2021
  • 资助金额:
    $ 24.09万
  • 项目类别:
Structural Basis of HDAC Substrate Specificity and Inhibition
HDAC 底物特异性和抑制的结构基础
  • 批准号:
    9394954
  • 财政年份:
    2017
  • 资助金额:
    $ 24.09万
  • 项目类别:
Unraveling the Origin of Pyrazinamide's Synergy with other anti-TB Drugs
揭示吡嗪酰胺与其他抗结核药物协同作用的起源
  • 批准号:
    9079347
  • 财政年份:
    2015
  • 资助金额:
    $ 24.09万
  • 项目类别:
Cellular biofactories for therapeutic protein synthesis in tumor microenvironment
肿瘤微环境中治疗性蛋白质合成的细胞生物工厂
  • 批准号:
    9114273
  • 财政年份:
    2015
  • 资助金额:
    $ 24.09万
  • 项目类别:
NAAA Inhibitors for pain and inflammation
NAAA 疼痛和炎症抑制剂
  • 批准号:
    8903152
  • 财政年份:
    2015
  • 资助金额:
    $ 24.09万
  • 项目类别:
Sphingolipid-mediated dysregulation of glucose and energy homeostasis by POMC neurons
POMC 神经元鞘脂介导的葡萄糖和能量稳态失调
  • 批准号:
    9050560
  • 财政年份:
    2015
  • 资助金额:
    $ 24.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了